Therapy Areas: Respiratory
AnHeart Therapeutics Launches Study to Evaluate AXL inhibitor AB-329 in Metastatic Breast Cancer
19 October 2021 - - US-based biopharmaceutical company AnHeart Therapeutics has launched sponsored research to evaluate AB-329, an AXL inhibitor in metastatic breast cancer, the company said.

The coprimary investigators of the study are Jangsoon Lee, Ph.D., and Naoto Ueno, M.D., both of The University of Texas MD Anderson Cancer Center.

In breast cancer, AXL expression independently predicts poor overall patient survival. Activation of AXL kinase activity or overexpression of AXL is associated with drug resistance in multiple cancers.

AnHeart Therapeutics is a clinical-stage global biopharmaceutical company developing novel precision oncology therapeutics.

Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first-line and second-line ROS1 fusion positive non-small cell lung cancer (NSCLC) and NTRK fusion positive solid tumors.

The company's pipeline also includes AB-218, an IDH1 inhibitor in Phase 2 trials for lower grade glioma, cholangiocarcinoma, AML and other tumors and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor and chemotherapies in NSCLC, ovarian cancer and breast cancers.

AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics with high unmet medical need. The company has offices in New York, Shanghai, Beijing and Hangzhou, China.


Related Headlines